Management of Acute Vomiting in Gastroparesis

First-Line Treatment

The American Gastroenterological Association recommends ondansetron 4-8 mg two to three times daily or granisetron 1 mg twice daily as first-line antiemetic therapy for acute vomiting in gastroparesis, as they effectively block serotonin receptors in the chemoreceptor trigger zone and inhibit vagal afferents 1, 2
Ondansetron and granisetron have similar efficacy, with selection depending on price, availability, and preferred delivery route, and are available in both parenteral and enteral forms for acute administration 1, 2

Metoclopramide is the only FDA-approved medication specifically for gastroparesis, providing dual prokinetic and antiemetic effects, and should be dosed at 5-20 mg three to four times daily 1, 2
The American College of Gastroenterology advises monitoring for extrapyramidal side effects and tardive dyskinesia with metoclopramide use, particularly with use beyond 12 weeks 3

Phenothiazine compounds, such as prochlorperazine 5-10 mg four times daily, provide alternative dopamine receptor blockade for acute vomiting in gastroparesis when 5-HT3 antagonists are insufficient 1, 2, 4
Aprepitant 80 mg daily may benefit up to one-third of patients with persistent nausea despite standard therapy by blocking substance P in critical nausea centers 1, 2

The American Gastroenterological Association recommends avoiding GLP-1 receptor agonists in gastroparesis patients, as they further delay gastric emptying and exacerbate symptoms 3
Synthetic cannabinoids, such as dronabinol and nabilone, should be avoided despite approval for chemotherapy-related nausea, as they may slow gastric emptying 2
Scopolamine lacks supporting clinical studies in gastroparesis despite off-label use 2